FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2329693846> ?p ?o ?g. }

• W2329693846 abstract "Objective: The study aims to investigate the cellular mode of action of laquinimod in experimental autoimmune encephalomyelitis (EAE), the animal model of multiple sclerosis. Background Laquinimod is an orally administered CNS-active immunomodulator. Phase III data in RRMS patients indicate a positive effects of laquinimod 0.6 mg on clinical disease activity as evidenced by slowing the progression of disability, reducing the rate of MRI-measured brain volume loss and reducing relapse rates, all coupled with a favorable safety and tolerability profile. In EAE, it has been shown that laquinimod acts on autoaggressive T cells by reducing proinflammatory Th1 cytokine production. However, the exact cellular and molecular mechanisms of laquinimod are still incompletely understood. Design/Methods: In this study we set out to test the efficacy of laquinimod in both preventive (application of laquinimod for 14 days starting at the time of immunization) and therapeutic (starting the treatment when first symptoms occurred for 7 days) regimens in the MOG 35-55 -induced murine EAE model. Using intravital two photon microscopy combined with molecular ex vivo -analyses we are currently evaluating the locomotion and function of pathogenic effector T cells during the different phases of EAE as well as their interaction with other immune cells. Results: Our preliminary results show that laquinimod is able to ameliorate EAE in a dose-dependent manner in MOG-induced C57Bl/6 EAE as well as in a more aggressive and fulminant model using transfer of transgenic MOG-specific T cells. This was observed both in the preventive and therapeutic setting. Furthermore, we observed reduced proliferation of MOG-specific T cells and a reduction in the expression of activation markers in the priming phase and later a reduced production of pro-inflammatory cytokines such as IFN-gamma and IL17. Conclusions: In our experimental model used, laquinimod was shown to act early on antigen-specific T cells in the priming/preclinical phase before symptoms start to occur. Supported by: TEVA. Disclosure: Dr. Luhder has received research support from Teva. Dr. Winchenbach has nothing to disclose. Dr. Flugel has received research support from Teva." @default.
• W2329693846 created "2016-06-24" @default.
• W2329693846 creator A5007466326 @default.
• W2329693846 creator A5012246833 @default.
• W2329693846 creator A5066404563 @default.
• W2329693846 date "2012-04-22" @default.
• W2329693846 modified "2023-09-24" @default.
• W2329693846 title "Analysis of Laquinimod Efficiency during Experimental Autoimmune Encephalomyelitis (P02.115)" @default.
• W2329693846 doi "https://doi.org/10.1212/wnl.78.1_meetingabstracts.p02.115" @default.
• W2329693846 hasPublicationYear "2012" @default.
• W2329693846 type Work @default.
• W2329693846 sameAs 2329693846 @default.
• W2329693846 citedByCount "0" @default.
• W2329693846 crossrefType "journal-article" @default.
• W2329693846 hasAuthorship W2329693846A5007466326 @default.
• W2329693846 hasAuthorship W2329693846A5012246833 @default.
• W2329693846 hasAuthorship W2329693846A5066404563 @default.
• W2329693846 hasConcept C150903083 @default.
• W2329693846 hasConcept C164027704 @default.
• W2329693846 hasConcept C203014093 @default.
• W2329693846 hasConcept C207001950 @default.
• W2329693846 hasConcept C26291073 @default.
• W2329693846 hasConcept C2776914184 @default.
• W2329693846 hasConcept C2778486448 @default.
• W2329693846 hasConcept C2780640218 @default.
• W2329693846 hasConcept C71924100 @default.
• W2329693846 hasConcept C86803240 @default.
• W2329693846 hasConcept C98274493 @default.
• W2329693846 hasConceptScore W2329693846C150903083 @default.
• W2329693846 hasConceptScore W2329693846C164027704 @default.
• W2329693846 hasConceptScore W2329693846C203014093 @default.
• W2329693846 hasConceptScore W2329693846C207001950 @default.
• W2329693846 hasConceptScore W2329693846C26291073 @default.
• W2329693846 hasConceptScore W2329693846C2776914184 @default.
• W2329693846 hasConceptScore W2329693846C2778486448 @default.
• W2329693846 hasConceptScore W2329693846C2780640218 @default.
• W2329693846 hasConceptScore W2329693846C71924100 @default.
• W2329693846 hasConceptScore W2329693846C86803240 @default.
• W2329693846 hasConceptScore W2329693846C98274493 @default.
• W2329693846 hasLocation W23296938461 @default.
• W2329693846 hasOpenAccess W2329693846 @default.
• W2329693846 hasPrimaryLocation W23296938461 @default.
• W2329693846 hasRelatedWork W1885429851 @default.
• W2329693846 hasRelatedWork W1902591712 @default.
• W2329693846 hasRelatedWork W1989527322 @default.
• W2329693846 hasRelatedWork W1990410752 @default.
• W2329693846 hasRelatedWork W2001642942 @default.
• W2329693846 hasRelatedWork W2018560721 @default.
• W2329693846 hasRelatedWork W2037580394 @default.
• W2329693846 hasRelatedWork W2079899001 @default.
• W2329693846 hasRelatedWork W2087580038 @default.
• W2329693846 hasRelatedWork W2126135538 @default.
• W2329693846 hasRelatedWork W2136681293 @default.
• W2329693846 hasRelatedWork W2319991398 @default.
• W2329693846 hasRelatedWork W2383523513 @default.
• W2329693846 hasRelatedWork W2523698717 @default.
• W2329693846 hasRelatedWork W2527211602 @default.
• W2329693846 hasRelatedWork W265581396 @default.
• W2329693846 hasRelatedWork W2765838604 @default.
• W2329693846 hasRelatedWork W2891362069 @default.
• W2329693846 hasRelatedWork W3081702740 @default.
• W2329693846 hasRelatedWork W2084353612 @default.
• W2329693846 isParatext "false" @default.
• W2329693846 isRetracted "false" @default.
• W2329693846 magId "2329693846" @default.
• W2329693846 workType "article" @default.